Powered by
-
BMY Stock Chart
Historical BMY Prices
Bristol-Myers Squibb Stock Analysis
Rating: Sell
Total Grade: D
Analysis Breakdown
| BMY Stock Grade: | D |
| Fundamental Grade: | D |
| Quantitative Grade: | D |
| BMY Earnings | |
| Earnings Growth: | F |
| Earnings Momentum: | D |
| Earnings Surprises: | C |
| Analyst Earnings Revisions: | C |
| BMY Financial Information | |
| Sales Growth: | D |
| Operating Margin Growth: | F |
| Cash Flow: | F |
| Return on Equity: | C |
Bristol-Myers Squibb Stock: Weekly View
| This Week: | D |
|---|---|
| Last Week: | C |
| Two Weeks Ago: | C |
BMY Stock predictions, Articles, and Bristol-Myers Squibb News
- From InvestorPlace
- From the Web
-
Stocks Push Forward As Fears of War Diminish - April 17, 2018
Stocks climbed again on Monday, shrugging off the U.S.-led airstrike on Syria over the weekend. Now the market will get an update on U.S. industrial production as well as a batch of Federal Reserve policymaker speeches. Continue…
-
5 Trades to Make First Thing Tomorrow Morning - April 16, 2018
On Monday we had be big moves from Bank of America, Starbucks, Ford and others. Here's 5 hot stocks to watch and what trades to make on Tuesday. Continue…
-
Mylan Stock is One Stumble Away From a Big Technical Pullback - March 21, 2018
Thinking about buying Mylan stock? You may not want to just yet. It's toying with a support line that, if it snaps, could open the selling floodgates. Continue…
-
At $65.63, Bristol-Myers Squibb Co (BMY) a Buy - March 2, 2018
At $65.63, Bristol-Myers Squibb Co (BMY) a Buy based on the latest stock market ratings, and comparative pricing of its shares. Continue…
-
Strong Quant Score Make Bristol-Myers Squibb Co (BMY) a Buy at recent price of $60.96 - February 6, 2018
The a Buy rating for BMY is based on the Portfolio Grader stock evaluator. The methodology for investing incorporated in this analytical tool researches and ranks nearly 5,000 stocks each week from a fundamental and quantitative perspective. BMY has maintained this ranking for the last month. Continue…
-
The Recent Selloff Is No Reason to Buy Bristol-Myers Squibb Co Stock - February 6, 2018
Bristol-Myers stock fell about 4% after reporting earnings. Is it because of its results, or a day where the broader markets fell about the same amount? Continue…
-
Bristol-Myers Squibb Co Earnings: 10 Things to Know About Q4 - February 5, 2018
Bristol-Myers Squibb (BMY) stock was down on Monday following the release of its earnings report for the fourth quarter of 2017. Continue…
-
The Future of Merck & Co., Inc. Stock Is With Keytruda - February 5, 2018
Merck & Co's cancer drug, Keytruda, saw explosive growth this quarter, making MRK stock a tough name to handicap right now. Continue…
-
Mastercard Inc Leads 6 Dividend Stocks Boosting Payouts - December 11, 2017
Six notable dividend stocks recently raised their payouts, including Mastercard (MA). Here's what you need to know about each. Continue…
-
Bristol-Myers Squibb Co (BMY) Industry Group Rank Penalize Rating - December 8, 2017
Bristol-Myers Squibb Co (NYSE:BMY) is a $103.5 billion in market value constituent of the Pharmaceuticals GICS industry group where Portfolio Grader's current ranking for BMY puts it 64 among the 134 companies in this industry group, placing it in the top half. BMY is ranked in the top half of the sector with a ranking of 370 among the 782 companies in the sector and number 2,185 in the 5000 company Portfolio Grader company universe. Continue…
